[D-Lys3]- GHRP- 6 CAS NO.136054-22-3

TECHNICAL SPECIFICATIONS

1.MECHANISM OF ACTION

[D-Lys3]-GHRP-6 functions primarily as a selective and competitive antagonist at the Growth Hormone Secretagogue Receptor 1a (GHSR-1a). It binds with high affinity to the ghrelin receptor but does not activate the downstream Gq/11-protein signaling cascade. By occupying the receptor's binding site, it prevents endogenous ghrelin and other agonists (e.g., GHRP-6, GHRP-2) from binding and initiating their biological effects.

2.PRODUCT INDICATIONS

Receptor Pharmacology: Used as a selective tool to block GHSR-1a in in vitroand in vivostudies, confirming the specific involvement of this receptor in observed physiological responses.
Appetite & Metabolism Research: Investigating the role of the ghrelin system in feeding behavior, energy homeostasis, and obesity by antagonizing central GHSR-1a signaling in animal models.
Growth Hormone Axis Studies: Studying the contribution of ghrelin-mediated vs. GHRH-mediated pathways in the pulsatile secretion of GH.
Cancer Research: Exploring the role of GHSR-1a signaling in the proliferation of certain cancer cell lines (e.g., breast, prostate) where ghrelin may act as a mitogen.
Control Experiments: Serving as an essential negative control in experiments using GHSR-1a agonists to verify that observed effects are receptor-specific.
Drug Discovery: Screening and characterizing new GHSR-1a ligands by using it as a reference antagonist in competition binding assays.

3.CLINICAL EFFICACY OF PRODUCT

Preclinical Research Efficacy: It is widely recognized as a potent and selective GHSR-1a antagonist in animal and cellular models. Studies demonstrate its effectiveness in suppressing ghrelin-induced GH release and food intake.
Therapeutic Target Validation: Research using this antagonist has been instrumental in validating GHSR-1a as a therapeutic target for conditions like obesity, cachexia, and certain cancers. It helps establish cause-and-effect relationships for ghrelin's actions.
Clinical Translation Gap: This specific peptide is not a drug candidate. However, the knowledge gained from its use supports the development of small-molecule GHSR-1a antagonists currently under investigation in clinical trials for obesity and metabolic disorders.
Status: No human clinical trials have been conducted with [D-Lys3]-GHRP-6. Its value is entirely in generating robust preclinical data to guide future therapeutic development.



4.DELIVERY & SHIPPING


We specialize in global logistics for various cosmetic peptides. Your order will be handled with the utmost care, ensuring safe, reliable, and intact delivery.
Professional and Secure Packaging
Each bottle of peptide is protected with a special packaging solution to ensure stability and integrity during transportation.
We can also customize packaging according to customer needs.
Shipping Methods 
Main Method: International Air Freight


We primarily use DHL, FedEx, UPS, and TNT because of their global reliability, speed, and advanced tracking systems. Air freight ensures the fastest transit time and minimizes the impact of environmental factors on the product.